The development or exacerbation of eating disorder symptoms after topiramate initiation

Jocelyn Lebow, Jeffrey A. Chuy, Kyle Cedermark, Katlyn Cook, Leslie A. Sim

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The Food and Drug Administration recently approved topiramate for migraine prevention in adolescents. Given the well-established appetite-suppressant side effects of topiramate, as well as data suggesting a potential comorbidity between migraine and eating disorders, susceptible young migraine patients may be at a greater risk for the development or worsening of eating disorder symptoms with topiramate therapy. This case series comprises 7 adolescent patients in whom serious eating disorders developed or were exacerbated after the initiation of topiramate therapy. Clinical characteristics of these patients are highlighted. In addition, this case series provides guidelines for providers to use in assessing eating disorders before prescribing topiramate for migraine prevention in adolescents.

Original languageEnglish (US)
Pages (from-to)e1312-e1316
JournalPediatrics
Volume135
Issue number5
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'The development or exacerbation of eating disorder symptoms after topiramate initiation'. Together they form a unique fingerprint.

Cite this